Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia.
about
Brief History and Characterization of Enhanced Respiratory Syncytial Virus DiseaseRespiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.Induction of Th-1 and Th-2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent.Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSVRespiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice.Conserved cysteine residues within the attachment G glycoprotein of respiratory syncytial virus play a critical role in the enhancement of cytotoxic T-lymphocyte responsesRole of CCL11 in eosinophilic lung disease during respiratory syncytial virus infectionActive and passive immunisation against respiratory syncytial virus.Evolution of bovine respiratory syncytial virus.Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice.CD4(+) T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment.Characterization of a novel respiratory syncytial virus-specific human cytotoxic T-lymphocyte epitope.Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism.Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.Immune responses and disease enhancement during respiratory syncytial virus infectionRespiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro.Dual role of respiratory syncytial virus glycoprotein fragment as a mucosal immunogen and chemotactic adjuvantNew insights for development of a safe and protective RSV vaccineProphylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T-lymphocyte response despite lacking major histocompatibility complex class I-restricted epitopes.The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P.Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice.Differential immune responses and pulmonary pathophysiology are induced by two different strains of respiratory syncytial virus.Host transcription profiles upon primary respiratory syncytial virus infectionNonglycosylated G-Protein Vaccine Protects against Homologous and Heterologous Respiratory Syncytial Virus (RSV) Challenge, while Glycosylated G Enhances RSV Lung Pathology and Cytokine Levels.Need for a safe vaccine against respiratory syncytial virus infection.Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthoodAtypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus.Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and BEnhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance PSingle intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infectionCharacterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein.Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination.A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice.Targeting RSV with vaccines and small molecule drugs.Pulmonary eosinophils and their role in immunopathologic responses to formalin-inactivated pneumonia virus of mice.Prospects for defined epitope vaccines for respiratory syncytial virus.Respiratory syncytial virus: immunopathology and control.Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention.
P2860
Q26775152-8700B8CE-5801-40C1-BA9B-8E55AC6DFAF4Q30240274-91328D59-D1BE-49FC-B638-97CE5E0E6934Q30304128-ED7D6A15-C85F-4FCB-BB6F-000F4F108E61Q30448968-9798FC02-1297-4B91-AA61-DD368FE45105Q33648461-9BE58026-AE16-4A31-AE34-C36B39A9C300Q33754172-4D30C1BC-1316-4AA1-A1E9-9FC90CB8351FQ33781375-E6A0CB04-AB83-4F1D-A712-50BFE8462149Q33782438-5CAD5D58-E5F1-4945-BE8A-3C60F76D1645Q33787341-BCE486CE-B0B2-43AC-9460-1A6C888A073CQ33797058-6C033D36-26AB-4DDE-9295-CAAA4EEA72F5Q33801890-D52DB791-0853-47A5-931D-A8B7A6AEFA24Q33810180-8298B1D8-0664-489B-9A3C-1A39D8F7E7FCQ33820420-4BCDD5F8-045E-4AF6-ADEF-64E69C552147Q33840469-54E2ADB5-210B-4368-BD3D-63967327EB60Q33937152-77345E40-D9DC-4B9D-B6E5-8CF31E07FFB2Q34151000-EB3BEF48-9457-4508-B6CD-F1936C4E4269Q34151865-6F7757AB-7DDC-44D5-A686-4A14D45FD914Q34182385-5B53D904-821D-478A-973A-404DDF004A73Q34249859-88E141C7-F62B-48BF-B225-8545C98BC443Q34262180-B4FAD797-E28D-4B92-B71B-1D163EE2703BQ34651258-66CE4FD5-DDF6-44E1-B073-FF6AC6AE22DCQ34996665-4978D8F3-04B9-4E68-B301-2F3825D37415Q35077892-C06BA2E4-4650-4A9A-8E88-E023C606A799Q35222083-19375D39-F53E-47F6-B7CC-2FF54F40A726Q35857662-C0EA73B6-92B3-4751-821E-9CB278A34BA7Q35914345-26A9D600-8B2E-4771-B4D9-FADEFEB002B7Q36266896-2097B86C-AE81-4B96-BED2-D9B6B9C87191Q36371040-4218E30E-8F0A-4DB8-949A-16085DF54496Q36401291-ABD2A31A-17CC-42B8-98C4-7B948004984FQ36453608-244CA2E0-C058-4807-84F4-5D2EF4B13998Q36464353-2F44019E-2393-4401-A5CC-93C4998B5E6AQ36483809-2C71E746-9441-4F10-869D-2BC450394CBEQ36684360-AA1DF423-9FA3-4811-AE85-2492E1E0A6F3Q36993991-5B1837EC-541A-49B9-99EE-42D128B9F2A5Q37252613-CEDDCEA0-3043-4707-A393-B5C0ECA4C459Q37328584-11256B86-E399-4A10-BB57-157AF3DD1EFEQ37369537-12EBD933-FE6C-4C98-820F-28DB875825EFQ37721415-BA7FC3C2-45A9-47B6-91A7-D0C379E190FCQ37754763-C07664CD-8B61-4488-A546-63EEDF47A4E8Q37841269-92CCD540-664A-48AF-A207-ED6603AB29C8
P2860
Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Eliminating a region of respir ...... ne-enhanced lung eosinophilia.
@ast
Eliminating a region of respir ...... ne-enhanced lung eosinophilia.
@en
type
label
Eliminating a region of respir ...... ne-enhanced lung eosinophilia.
@ast
Eliminating a region of respir ...... ne-enhanced lung eosinophilia.
@en
prefLabel
Eliminating a region of respir ...... ne-enhanced lung eosinophilia.
@ast
Eliminating a region of respir ...... ne-enhanced lung eosinophilia.
@en
P2093
P2860
P50
P356
P1476
Eliminating a region of respir ...... ine-enhanced lung eosinophilia
@en
P2093
B Garcia-Barreno
P J Openshaw
S Matthews
P2860
P304
P356
10.1084/JEM.187.11.1921
P407
P577
1998-06-01T00:00:00Z